← Compare landing
Merck KGaA vs ProBio
Side-by-side profile data from each company listing. Missing fields stay blank rather than filled with assumptions.
| Category | Merck KGaA | ProBio |
|---|---|---|
| Summary | Recent coverage reports that Merck KGaA plans to sell its life science CDMO business to Lonza. The same coverage describes a new €300 million bioprocessing center in Daejeon, South Korea. | ProBio is a leading global CDMO subsidiary of GenScript Biotech Corporation, providing end-to-end services for biologics and cell & gene therapy (CGT) from drug discovery through commercialization. |
| Services | Data not yet provided. |
|
| Modalities | Data not yet provided. |
|
| Development capabilities | Data not yet provided. | Data not yet provided. |
| Manufacturing capabilities | Data not yet provided. | Data not yet provided. |
| Locations |
|
|
| Certifications | Data not yet provided. |
|
Find similar companies
Markdown mirror: /compare/merck-kgaa/probio.md